Hungarian Richter agrees on Esmya intellectual property rights with HRA Pharma
Hungarian drug producer Gedeon Richter on Thursday said it concluded a sale and purchase agreement with France's Laboratoire HRA Pharma in connection with intellectual property rights of ulipristal acetate, the active ingredient in Esmya, a Richter drug for the treatment of uterine fibroids, in Latin America.
Richter did not disclose the financial terms of the agreement. “This transaction is considered to be a further strategic move to strengthen Richter’s direct position in Latin America and at the same time to become gradually a global female healthcare player”, said CEO Erik Bogsch.
Richter obtained from HRA Pharma an extension of its geographical scope for Esmya to the CIS and China in December 2011. A year ago, Richter entered into a licencing agreement with HRA Pharama in connection with market rights in Latin America for ulipristal acetate.
Watson Pharmaceuticals has exclusive rights to develop and market Esmya in the United States and Canada.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.